Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) have been given an average rating of “Buy” by the six research firms that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation, four have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $55.60.

Several brokerages have recently issued reports on TARS. The Goldman Sachs Group increased their price objective on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a “neutral” rating in a research report on Friday, November 15th. Oppenheimer raised their target price on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” rating in a research note on Wednesday.

Institutional Trading of Tarsus Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in TARS. Jennison Associates LLC increased its position in shares of Tarsus Pharmaceuticals by 14.8% in the fourth quarter. Jennison Associates LLC now owns 2,500,132 shares of the company’s stock worth $138,432,000 after purchasing an additional 321,552 shares during the period. China Universal Asset Management Co. Ltd. lifted its stake in shares of Tarsus Pharmaceuticals by 10.8% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,106 shares of the company’s stock valued at $449,000 after acquiring an additional 789 shares during the last quarter. Baader Bank Aktiengesellschaft bought a new position in Tarsus Pharmaceuticals in the fourth quarter valued at about $249,000. R Squared Ltd bought a new position in shares of Tarsus Pharmaceuticals during the fourth quarter valued at $53,000. Finally, Assenagon Asset Management S.A. raised its position in Tarsus Pharmaceuticals by 0.5% during the 4th quarter. Assenagon Asset Management S.A. now owns 1,146,812 shares of the company’s stock worth $63,499,000 after purchasing an additional 5,565 shares during the last quarter. 90.01% of the stock is currently owned by institutional investors.

Tarsus Pharmaceuticals Stock Down 0.7 %

Shares of Tarsus Pharmaceuticals stock opened at $48.78 on Friday. The business has a 50-day moving average of $51.04 and a two-hundred day moving average of $38.94. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38. Tarsus Pharmaceuticals has a 1 year low of $20.08 and a 1 year high of $57.14. The company has a market capitalization of $1.86 billion, a P/E ratio of -12.80 and a beta of 1.02.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.